熱門資訊> 正文
PacBio宣布对其Revio和Vega平台进行创新，以降低测序成本、增加新的多元能力并扩大对受监管研究环境的支持
2025-10-14 18:07
- The advancements center on new SPRQ-Nx sequencing chemistry and consumables, which are designed to deliver PacBio's most affordable HiFi genome to date. Customers operating at scale could see as much as a 40% reduction from current costs, down to a price of less than $300 per genome. Additional improvements include 5hmC detection for epigenetic profiling and 21 CFR Part 11 compliance features for Vega. These updates reflect PacBio's continued investment in making its highly accurate long-read sequencing solutions accessible at scale for population genomics, clinical research, and production-scale environments.
- Beta testing of SPRQ-Nx chemistry on the higher throughput Revio is expected to begin in November 2025, with full commercial availability planned in 2026. Beta participants will be able to purchase 384 genomes of sequencing reagents for approximately $250 per genome. At launch, Revio systems running SPRQ-Nx will produce complete, multiomic native long-read genomes at the lowest cost in the market. PacBio intends to achieve these cost savings by enabling multiple runs per SMRT Cell while maintaining output per run, which will improve efficiency, reduce waste, and preserve PacBio's hallmark accuracy and data richness.
- Vega, PacBio's benchtop system, will integrate SPRQ-Nx chemistry and 5hmC detection capabilities in 2026. Vega will also add rapid two- and four-hour sequencing runs, designed for high-demand applications such as plasmid and targeted sequencing. These upgrades will include secure authentication and audit logging features to support 21 CFR Part 11 compliance for labs operating under regulated conditions.
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
